Thursday, January 07, 2010
JAMA analysis questions antidepressant drug benefits
07 January 2010
Another meta-analysis has cast doubt on the effectiveness of drug therapy as a strategy for tackling depression, specifically the less severe forms of the disease.
The study published in the Journal of the American Medical Association (JAMA) found that in six trials involving treatment with paroxetine (GlaxoSmithKline’s Paxil, Seroxat), the genericised imipramine or placebo, the benefits of medication versus placebo were “non-existent to negligible” among patients with mild, moderate or even severe symptoms of depression, whereas in patients with very severe depression the effects were substantial.
Read more here
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
About the Author :
Bob Fiddaman has been writing about the dangers of antidepressants since 2006. In 2011 he was presented with two human rights awards from the Citizens Commission on Human Rights.
Labels: bobfiddaman, Fiddaman, fiddaman blog, Paroxetine, Paxil, Seroxat, Seroxat Sufferers, Seroxat Sufferers Stand Up and be Counted, SSRis, THE EVIDENCE HOWEVER IS CLEAR